Tag:
Dendreon
Latest Headlines
Latest Headlines
NEJM spotlights Provenge study
Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues, cost
NEJM lays out questions--and facts--about Provenge
Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and
Dendreon shares routed by Medicare Provenge review news
Shares of Dendreon (DNDN) took a nasty hit on Wednesday after Medicare officials announced plans to review its new prostate cancer vaccine to see whether the federal program should pay to provide it
Dendreon scrambles to boost Provenge production
Dendreon is ramping up production of its brand-new prostate cancer vaccine Provenge-- but not nearly fast enough. The supply will fall far short of demand for at least the next 12 months. Only two
Provenge gets clean bill of health on safety, side effects
Dendreon's (NASDAQ: DNDN) megablockbuster launch of the prostate cancer vaccine Provenge got an added boost earlier in the week when researchers unveiled a new block of data that underscores the
Who's the next Dendreon?
One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (NASDAQ: DNDN), which braved some considerable
Personalized manufacturing will limit Provenge supply
A lack of manufacturing bandwidth is putting the squeeze on Dendreon's newly approved immunotherapy, Provenge. The prostate cancer drug's demanding manufacturing process is so far approved in only
FDA approves Provenge for prostate cancer
Amongst the daily catch of healthcare-related news releases, some announcements are just more important than others. That's certainly the case with Dendreon's announcement that the FDA has approved
Dendreon CEO cashes in $28.8M of shares on Provenge OK
Dendreon (NASDAQ: DNDN) CEO Mitchell Gold had a busy day last Thursday, when the FDA capped the developer's 15-year quest with an approval of the revolutionary new prostate cancer vaccine Provenge.
Dendreon: Provenge to cost $93K for full course of treatment
One of the most pressing questions analysts and patients have had about Provenge is how much Dendreon would charge for its newly approved prostate cancer drug. Following this afternoon's conference
